• 1
    Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368:436445.
  • 2
    Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28:555565.
  • 3
    Vora SA, Wong WW, Schild SE, et al. 9-Year outcome and toxicity in patients treated with intensity modulated radiation therapy for localized prostate cancer. J Urol. 2013;doi:10.1016/j.juro.2013.02.012.
  • 4
    Carroll PR, Albertsen PC, Grene K, et al. American Urological Association Best Practice Statement. Prostate-Specific Antigen: 2009 Update. Accessed May 15, 2013.
  • 5
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer 2013. Accessed May 15, 2013.
  • 6
    Trantham LC, Nielsen ME, Mobley LR, Wheeler SB, Carpenter WR, Biddle AK. Use of prostate-specific antigen testing as a disease surveillance tool following radical prostatectomy. Cancer. 2013;119:35233530.
  • 7
    Chamie K, Saigal CS, Lai J, et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer. 2011;117:53925401.
  • 8
    Madeb R, Golijanin D, Noyes K, et al. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer. 2009;115:26602670.
  • 9
    Burks FN, Liu AB, Suh RS, et al. Understanding the use of immediate intravesical chemotherapy for patients with bladder cancer. J Urol. 2012;188:21082113.
  • 10
    Miller DC, Murtagh DS, Suh RS, et al. Regional collaboration to improve radiographic staging practices among men with early stage prostate cancer. J Urol. 2011;186:844849.
  • 11
    Michigan Urological Surgery Improvement Collaborative (MUSIC). Accessed May 15, 2013.
  • 12
    The Foundation for Health Care Quality. Surgical Care and Outcomes Assessment Program (SCOAP). Accessed May 15, 2013.
  • 13
    Skolarus TA, Zhang Y, Hollenbeck BK. Understanding fragmentation of prostate cancer survivorship care: implications for cost and quality. Cancer. 2012;118:28372845.
    Direct Link:
  • 14
    Hewett M, Greenfield S, Stovall E, eds. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: National Academies Press; 2005.
  • 15
    Earle CC, Ganz PA. Cancer survivorship care: don't let the perfect be the enemy of the good. J Clin Oncol. 2012;30:37643768.
  • 16
    McCabe MS, Bhatia S, Oeffinger KC, et al. American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol. 2013;31:631640.
  • 17
    Earle CC. Failing to plan is planning to fail: improving the quality of care with survivorship care plans. J Clin Oncol. 2006;24:51125116.
  • 18
    Salz T, Oeffinger KC, McCabe MS, Layne TM, Bach PB. Survivorship care plans in research and practice. CA Cancer J Clin. 2012; doi:10.3322/caac.20142.
  • 19
    LIVESTRONG Care Plan. Accessed May 23, 2013.